Shlomi Matetzky

Dr. Shlomi Matetzky


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in BMC Medicine
Verified
Journal Article
Open access
PDF file
FIfor the Israel Heart Failure Disease Management Study (IHF-DMS) investigators
for the Israel Heart Failure Disease Management Study (IHF-DMS) investigators
OKOfra Kalter-Leibovici
Ofra Kalter-Leibovici
DFDov Freimark
Dov Freimark
LFLaurence S. Freedman
Laurence S. Freedman
GKGalit Kaufman
Galit Kaufman
HSHaim Silber
Haim Silber
The efficacy of disease management programs in improving the outcome of heart failure patients remains uncertain and may vary across health systems. This study explores whether a countrywide disease management program is superior to usual care in reducing adverse health outcomes and improving well-being among community-dwelling adult patients with moderate-to-severe chronic heart failure who have universal access to advanced health-care services and technologies. In this multicenter open-label trial, 1,360 patients recruited after hospitalization for heart failure exacerbation (38%) or from the community (62%) were randomly assigned to either disease management or usual care. Disease management, delivered by multi-disciplinary teams, included coordination of care, patient education, monitoring disease symptoms and patient adherence to medication regimen, titration of drug therapy, and home tele-monitoring of body weight, blood pressure and heart rate. Patients assigned to usual care were treated by primary care practitioners and consultant cardiologists. The primary composite endpoint was the time elapsed till first hospital admission for heart failure exacerbation or death from any cause. Secondary endpoints included the number of all hospital admissions, health-related quality of life and depression during follow-up. Intention-to-treat comparisons between treatments were adjusted for baseline patient data and study center. During the follow-up, 388 (56.9%) patients assigned to disease management and 387 (57.1%) assigned to usual care had a primary endpoint event. The median (range) time elapsed until the primary endpoint event or end of study was 2.0 (0–5.0) years among patients assigned to disease management, and 1.8 (0–5.0) years among patients assigned to usual care (adjusted hazard ratio, 0.908; 95% confidence interval, 0.788 to 1.047). Hospital admissions were mostly (70%) unrelated to heart failure. Patients assigned to disease management had a better health-related quality of life and a lower depression score during follow-up. This comprehensive disease management intervention was not superior to usual care with respect to the primary composite endpoint, but it improved health-related quality of life and depression. A disease-centered approach may not suffice to make a significant impact on hospital admissions and mortality in patients with chronic heart failure who have universal access to health care. Clinicaltrials.gov identifier: NCT00533013 . Trial registration date: 9 August 2007. Initial protocol release date: 20 September 2007.

1 July 2018 in General Hospital Psychiatry
Verified
Journal Article
Closed access
KFKeren Fait
Keren Fait
NVNoa Vilchinsky
Noa Vilchinsky
RDRachel Dekel
Rachel Dekel
NLNitza Levi
Nitza Levi
HHHanoch Hod
Hanoch Hod
SMShlomi Matetzky
Shlomi Matetzky

1 January 2014 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
Elad AsherElad Asher
Elad Asher
PFPaul Fefer
Paul Fefer
MSMichael Shechter
Michael Shechter
RBRoy Beigel
Roy Beigel
DVDavid Varon
David Varon
SMShlomi Matetzky
Shlomi Matetzky
Summary: Prior studies have demonstrated significant individual variability of platelet response to clopidogrel, which affects clinical outcome. In patients with stable coronary artery disease (CAD) smoking, diabetes mellitus, elevated body mass index and renal insufficiency, significantly impact response to clopidogrel. The determinants of platelet response to clopidogrel in patients with acute coronary syndrome are unknown. Adenosine diphosphate (ADP)-induced platelet aggregation (PA), hs C-reactive protein, platelet count and mean platelet volume (MPV) were determined 72 hours post clopidogrel loading in 276 consecutive acute myocardial infarction (AMI) patients. Patients with ADP-platelet aggregation ≥ 70% were considered to be clopidogrel non-responders. Eighty-four patients (30%) were clopidogrel non-responders and 192 (70%) were responders (ADP-induced PA: 81 ± 17% vs 49 ± 17%, respectively, p<0.001). Both study groups were comparable with respect to age, gender, prior cardiovascular history, prior aspirin use and risk factors for CAD, including smoking (42% for both groups) and diabetes mellitus (26% vs 22%, respectively, p=0.4). Responders and non-responders had similar angiographic characteristics, indices of infarct size, and similar hs-CRP (29 ± 34 vs 28 ± 34 mg/l, p=0.7) and creatinine (1.08 ± 0.4 mg% vs 1.07 ± 0.4, p=0.9) levels. On the contrary non-responders had significantly larger mean MPV (9 ± 1.2 fl vs 8 ± 1 fl, respectively, p=0.0018), and when patients were stratified into quartiles based on MPV, ADP-induced PA increased gradually and significantly across the quartiles of MPV (p<0.001). In conclusion, increased MPV associated with platelet activation, predicts non-responsiveness to clopidogrel among patients with acute coronary syndrome.

1 September 2008 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SMShlomi Matetzky
Shlomi Matetzky
PFPaul Fefer
Paul Fefer
BSBoris Shenkman
Boris Shenkman
DVDavid Varon
David Varon
Naphtali SavionNaphtali Savion
Naphtali Savion
HHHanoch Hod
Hanoch Hod

29 October 2010 in Platelets
Verified
Journal Article
Closed access
PDF file
SMShlomi Matetzky
Shlomi Matetzky
PFPaul Fefer
Paul Fefer
BSBoris Shenkman
Boris Shenkman
MSMichael Shechter
Michael Shechter
INIlia Novikov
Ilia Novikov
MDMd
Md
Statins confer an antiplatelet effect in hypercholesterolemic subjects and in stable coronary artery disease patients. We explored the antiplatelet effects of statins in ST-elevation myocardial infarction (STEMI) patients undergoing primary angioplasty. Of 120 STEMI patients, 80 (67%) received statins while 40 (33%) did not. Ex vivo platelet reactivity was studied on admission and 72 hours later by conventional aggregometry and under flow conditions (Impact R). Measures of platelet reactivity under flow conditions included aggregate size and surface coverage, signifying platelet aggregation and adhesion respectively. The effect of statins on platelet function under flow conditions and platelet aggregation was studied in vitro in platelets from 10 STEMI patients. Platelets from each patient were incubated in vitro with lovastatin or PBS as a control. The effect of lovastatin in the presence of a nitric oxide synthase inhibitor (L-NMMA) was also studied. Patients treated with statins were compared with those who did not have significantly lower ADP-induced platelet aggregation on the 4th day (56 ± 18% vs. 64 ± 17%, p = 0.02). Platelet deposition under flow conditions as measured by surface coverage was reduced from admission to 72 hours later among statin-treated patients (19 ± 28% reduction, p < 0.01), but was unchanged in non-treated patients (for comparison p < 0.01). The extent of platelet inhibition was unrelated to patient characteristics, including lipid profile and type of statin administered (lipophylic vs. hydrophilic). In the in vitro study platelet incubation with statin compared with PBS resulted in a lower aggregate-size (29 ± 9 µm2 vs. 39 ± 15 µm2, p < 0.01), and lower surface coverage (8.5 ± 4% vs. 12 ± 4%, p < 0.01). The effect of the statin on both parameters was significantly blunted by L-NMMA. Incubation with statin also resulted in a reduction in collagen-induced platelet aggregation (31 ± 20% vs. 54 ± 25%, p < 0.01). We concluded that in acute myocardial infarction patients, statins have an early antiplatelet effect, in addition to that afforded by standard antiplatelet therapy.

1 January 2013 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
ELEyal Leibovitz
Eyal Leibovitz
SGShmuel Gottlieb
Shmuel Gottlieb
IGIlan Goldenberg
Ilan Goldenberg
NGNatalie Gevrielov-Yusim
Natalie Gevrielov-Yusim
SMShlomi Matetzky
Shlomi Matetzky
DGDov Gavish
Dov Gavish
Chronic treatment with currently available oral hypoglyemic medications may result in a differential effect on the clinical presentation of diabetic patients with acute coronary syndrome (ACS).